Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Jetstar to Charge for Overhead Cabin Bags From February 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
Heidelberg, Germany, March 13, 2018 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today announced that on March 20, 2018, the Company will release its financial results for the quarter and year ended December 31, 2017. The Company's management team will host a conference call to discuss the Company's financial results and recent corporate developments on Tuesday, March 20, 2018 at 8:30 a.m. ET. The call can be accessed by dialing one of the numbers listed below five minutes prior to the start of the call and providing the confirmation code 3160515.
United States: +1 786-789-4776
Germany: +49 (0)69 2222 13420
Netherlands: +31 (0) 20 721 9251
Denmark: +45 35 15 80 49
France: +33 (0)1 76 77 22 74
Switzerland: +41 (0)22 567 5729
United Kingdom:+44 (0)330 336 9105
An audio webcast of the conference call can be accessed in the "Events" section on the "Investors & Media" page of the Affimed website at www.affimed.com/events.php. A replay of the webcast will be available on Affimed's website shortly after the conclusion of the call and will be archived on the Affimed website for 30 days following the call.
About Affimed N.V.
Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK and T cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit www.affimed.com.
Contact:
Anca Alexandru, Head of Communications, EU IR
Phone: +49 6221 64793341
E-Mail: [email protected], [email protected]
